. Evaluation of the PMI in HCC patients only (n = 46). (A) Patients who showed an objective response (OR) to TACE therapy have a similar PMI compared to non-responding (non-OR) patients. (B) HCC patients with a pre-interventional PMI below the 50th percentile show a trend towards an impaired prognosis. (C) Kaplan-Meier curve analysis shows a strong trend towards a reduced overall survival for sarcopenic patients with a pre-interventional PMI below 13.39 mm/m 2 . (D) HCC patients with a low combined PMI*albumin score show a strikingly reduced overall survival. (E) Patients with a post-interventional PMI below the ideal cut-off value (11.48 mm/m 2 ) show a strong trend towards an impaired long-term survival following TACE therapy. (F) HCC patients with progressive sarcopenia after TACE (negative ∆PMI) show a significantly reduced overall survival compared to patients with a reduced level of sarcopenia after therapy (positive ∆PMI).
. Evaluation of the PMI in HCC patients only (n = 46). (A) Patients who showed an objective response (OR) to TACE therapy have a similar PMI compared to non-responding (non-OR) patients. (B) HCC patients with a pre-interventional PMI below the 50th percentile show a trend towards an impaired prognosis. (C) Kaplan-Meier curve analysis shows a strong trend towards a reduced overall survival for sarcopenic patients with a pre-interventional PMI below 13.39 mm/m 2 . (D) HCC patients with a low combined PMI*albumin score show a strikingly reduced overall survival. (E) Patients with a post-interventional PMI below the ideal cut-off value (11.48 mm/m 2 ) show a strong trend towards an impaired long-term survival following TACE therapy. (F) HCC patients with progressive sarcopenia after TACE (negative ∆PMI) show a significantly reduced overall survival compared to patients with a reduced level of sarcopenia after therapy (positive ∆PMI). 
